Key result
In patients with stable coronary artery disease, 12 months of treatment with aspirin alone reduced F1+2 levels significantly more than clopidogrel alone (p=0.023).
Why the study?
Does clopidogrel compared to aspirin reduce hypercoagulability markers in patients with stable coronary artery disease?
Population
1001 patients with angiographically verified stable coronary artery disease, mean age 62, 78% male, from a…
Comparison
Clopidogrel 75 mg/day oral for 12 months vs Continuous treatment with aspirin 160 mg/day…
Design
RCT, randomized to either continous treatment with aspirin or to change to…
Follow-up
12 months
Authors
Loading...
Aspirin attenuates thrombin generation more than clopidogrel in stable CAD; challenges assumptions of equivalent antithrombotic effects on coagulation markers.
RCT (n=1,001)
Randomized
No
Does clopidogrel compared to aspirin reduce hypercoagulability markers in patients with stable coronary artery disease?
Absolute Event Rate: 196% vs 205%
p-value: p=0.023
Long-term antiplatelet treatment with aspirin alone attenuates in vivo thrombin generation to a greater extent than clopidogrel alone in patients with stable CAD.
Bratseth et al. (2012) conducted an RCT in Stable coronary artery disease (n=1,001). Aspirin vs. Clopidogrel 75 mg/day was evaluated on Change in prothrombin fragment 1+2 (F1+2) levels at 12 months (p=0.023). In patients with stable coronary artery disease, 12 months of treatment with aspirin alone reduced F1+2 levels significantly more than clopidogrel alone (p=0.023).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: